Keyword: CRISPR Therapeutics
CRISPR Therapeutics is partnering with ViaCyte to develop off-the-shelf, gene-edited stem cell therapies for diabetes in a deal worth up to $25 million.
In a blow to the University of California, a federal appeals court upheld CRISPR patents held by the Broad Institute.
Inscripta aims to broaden access to CRISPR by offering new enzymes for free, and to boost R&D by outfitting scientists with a full suite of tools.
ProQR Therapeutics reported interim phase 1/2 data for its LCA10 treatment showing it improved vision for the majority of patients.
CRISPR Therapeutics and Vertex Pharmaceuticals will test their gene therapy in patients with beta thalassemia.
Editas Medicine is to lose its chief medical officer at the end of the year, as the search is on for a new clinical leader.
Another study warns of potential toxicity with CRISPR gene-editing, and gives investors in biotechs developing the technology the jitters.
Two new studies show that CRISPR editing could raise the risk of edited cells developing tumors.
Shares in CRISPR fell 15% as investors digested the delay to the start of the gene-editing startup’s first U.S. clinical trial.
Mammoth Biosciences is developing a CRISPR-based platform to detect any biomarker containing DNA or RNA.